Detalhe da pesquisa
1.
Inhibition of Hepatobiliary Transport Activity by the Antibacterial Agent Fusidic Acid: Insights into Factors Contributing to Conjugated Hyperbilirubinemia/Cholestasis.
Chem Res Toxicol
; 29(10): 1778-1788, 2016 Oct 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-27676153
2.
Toxicity assessments of nonsteroidal anti-inflammatory drugs in isolated mitochondria, rat hepatocytes, and zebrafish show good concordance across chemical classes.
Toxicol Appl Pharmacol
; 272(2): 272-80, 2013 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23811329
3.
Characterization of allosteric modulators that disrupt androgen receptor co-activator protein-protein interactions to alter transactivation-Drug leads for metastatic castration resistant prostate cancer.
SLAS Discov
; 2023 Aug 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37549772
4.
Screening for Neurotoxicity with Microelectrode Array.
Curr Protoc Toxicol
; 79(1): e67, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30575314
5.
Assays to Interrogate the Ability of Compounds to Inhibit the AF-2 or AF-1 Transactivation Domains of the Androgen Receptor.
Assay Drug Dev Technol
; 17(8): 364-386, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31502857
6.
Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells.
Cancer Res
; 66(15): 7509-15, 2006 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16885348
7.
High Content Positional Biosensor Assay to Screen for Compounds that Prevent or Disrupt Androgen Receptor and Transcription Intermediary Factor 2 Protein-Protein Interactions.
Methods Mol Biol
; 1683: 211-227, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29082495
8.
In Vitro Screening for Seizure Liability Using Microelectrode Array Technology.
Toxicol Sci
; 163(1): 240-253, 2018 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29432603
9.
High-Content Screening Campaign to Identify Compounds That Inhibit or Disrupt Androgen Receptor-Transcriptional Intermediary Factor 2 Protein-Protein Interactions for the Treatment of Prostate Cancer.
Assay Drug Dev Technol
; 16(6): 297-319, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30109944
10.
The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway.
Mol Cell Biol
; 23(2): 543-54, 2003 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-12509453
11.
Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer.
J Clin Endocrinol Metab
; 91(1): 79-84, 2006 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-16263812
12.
CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth.
Cancer Res
; 63(17): 5559-63, 2003 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-14500395
13.
Reconfiguring the AR-TIF2 Protein-Protein Interaction HCS Assay in Prostate Cancer Cells and Characterizing the Hits from a LOPAC Screen.
Assay Drug Dev Technol
; 14(8): 453-477, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27606620
14.
Identification of Drug-Drug Interactions In Vitro: A Case Study Evaluating the Effects of Sofosbuvir and Amiodarone on hiPSC-Derived Cardiomyocytes.
Toxicol Sci
; 154(1): 174-182, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27503387
15.
High content screening biosensor assay to identify disruptors of p53-hDM2 protein-protein interactions.
Methods Mol Biol
; 1278: 555-65, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25859976
16.
High-content positional biosensor screening assay for compounds to prevent or disrupt androgen receptor and transcriptional intermediary factor 2 protein-protein interactions.
Assay Drug Dev Technol
; 12(7): 395-418, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25181412
17.
Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling.
Cancer Res
; 70(11): 4460-9, 2010 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20484029
18.
Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2.
Assay Drug Dev Technol
; 8(4): 437-58, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20662736
19.
Implementation of a 220,000-compound HCS campaign to identify disruptors of the interaction between p53 and hDM2 and characterization of the confirmed hits.
J Biomol Screen
; 15(7): 766-82, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20639499
20.
Cellular systems biology profiling applied to cellular models of disease.
Comb Chem High Throughput Screen
; 12(9): 838-48, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19531002